If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback